Antiviral treatment and virological monitoring of oseltamivir-resistant influenza virus A(H1N1)pdm09 in a patient with chronic B lymphocytic leukemia

J Infect Chemother. 2019 Jul;25(7):543-546. doi: 10.1016/j.jiac.2018.11.008. Epub 2019 Apr 20.

Abstract

We report the virological monitoring and the antiviral therapy adopted for the treatment of a patient affected by chronic B lymphocytic leukemia, who experienced a severe pneumonia with long-term shedding of influenza virus A(H1N1)pdm09, characterized by an early development of oseltamivir resistance.

Keywords: A(H1N1)pdm09; Chronic lymphocytic leukemia; Influenza virus; Oseltamivir resistance; Triple-combination antiviral drug therapy (TCAD); Zanamivir.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antiviral Agents / pharmacology*
  • Antiviral Agents / therapeutic use
  • Drug Resistance, Viral
  • Drug Therapy, Combination
  • Female
  • Humans
  • Influenza A Virus, H1N1 Subtype / isolation & purification
  • Influenza A Virus, H1N1 Subtype / physiology*
  • Influenza, Human / complications
  • Influenza, Human / drug therapy*
  • Influenza, Human / virology
  • Leukemia, Lymphocytic, Chronic, B-Cell / complications*
  • Oseltamivir / pharmacology
  • Oseltamivir / therapeutic use
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / virology
  • Treatment Outcome
  • Virus Shedding
  • Zanamivir / pharmacology
  • Zanamivir / therapeutic use

Substances

  • Antiviral Agents
  • Oseltamivir
  • Zanamivir